Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
2.090
-0.190 (-8.33%)
At close: Dec 19, 2025, 4:00 PM EST
2.140
+0.050 (2.37%)
After-hours: Dec 19, 2025, 7:56 PM EST
Daré Bioscience Revenue
Daré Bioscience had revenue of $2.26K in the quarter ending September 30, 2025, a decrease of -94.57%. This brings the company's revenue in the last twelve months to $-57.13K. In the year 2024, Daré Bioscience had annual revenue of $9.78K, down -99.65%.
Revenue (ttm)
$-57.13K
Revenue Growth
-99.65%
P/S Ratio
-522.75
Revenue / Employee
n/a
Employees
23
Market Cap
29.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
| Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
| Dec 31, 2022 | 10.00M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 80.00K | 74.00K | 1,233.33% |
| Dec 31, 2013 | 6.00K | -619.00K | -99.04% |
| Dec 31, 2012 | 625.00K | 619.00K | 10,316.67% |
| Dec 31, 2011 | 6.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DARE News
- 11 days ago - DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - GlobeNewsWire
- 4 weeks ago - Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript - Seeking Alpha
- 5 weeks ago - Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 - GlobeNewsWire
- 3 months ago - Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research - GlobeNewsWire
- 4 months ago - Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire